Aptinyx to Participate in Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX) has announced its participation in two investor conferences. On June 22, CEO Norbert Riedel will join the panel on "Hot Topics in Neurological Disorder Therapeutics and Technologies" at the Oppenheimer Biotech by the Lake 2021 Investor Summit. Following that, on June 29, the management will engage in a fireside chat, "Validating the Mechanism of NMDA Modulation," during the SVB Leerink CNS Forum. Aptinyx is focused on developing therapies for nervous system disorders, with significant clinical candidates targeting chronic pain, PTSD, and cognitive impairment.
- None.
- None.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the Company will be participating in two upcoming investor conferences:
- Oppenheimer Biotech by the Lake 2021 Investor Summit – Norbert Riedel, Ph.D., chief executive officer, will participate in the “Hot Topics in Neurological Disorder Therapeutics and Technologies” Panel discussion on Tuesday, June 22 at 11:25 a.m. ET; and
- SVB Leerink CNS Forum (webcast available to clients of SVB Leerink) – Aptinyx management will participate in a fireside chat titled, “Validating the Mechanism of NMDA Modulation” on Tuesday, June 29 at 9:20 a.m. ET
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005124/en/
FAQ
What events is Aptinyx participating in June 2021?
Who is presenting for Aptinyx at the Oppenheimer conference?
What is the focus of Aptinyx's product candidates?
When will Aptinyx's fireside chat occur?
What is APTX's main therapeutic focus?
